Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High – Time to Buy?

Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) reached a new 52-week high during trading on Monday . The stock traded as high as $15.31 and last traded at $15.12, with a volume of 2903073 shares trading hands. The stock had previously closed at $15.16.

Takeda Pharmaceutical Price Performance

The firm has a market capitalization of $48.08 billion, a price-to-earnings ratio of 37.79, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The company’s 50 day moving average is $13.96 and its 200 day moving average is $13.91.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Trust Advisors LP increased its position in Takeda Pharmaceutical by 2.0% during the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company’s stock valued at $42,910,000 after purchasing an additional 62,718 shares during the period. FMR LLC increased its position in Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after purchasing an additional 286,052 shares during the period. Van ECK Associates Corp grew its position in shares of Takeda Pharmaceutical by 1.6% during the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock worth $29,266,000 after buying an additional 35,192 shares during the period. Northern Trust Corp grew its position in shares of Takeda Pharmaceutical by 14.6% during the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company’s stock worth $24,806,000 after buying an additional 238,161 shares during the period. Finally, Managed Asset Portfolios LLC grew its position in shares of Takeda Pharmaceutical by 0.3% during the 3rd quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company’s stock worth $23,001,000 after buying an additional 4,069 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.